Phase 1 clinical trial evaluating safety, exposure and pharmacodynamics of BTK inhibitor tolebrutinib (PRN2246, SAR442168)

Phase 1 clinical trial evaluating safety, exposure and pharmacodynamics of BTK inhibitor tolebrutinib (PRN2246, SAR442168)

Abstract Bruton’s tyrosine kinase (BTK), expressed in B cells and cells of innate immunity, including microglia, is an essential signaling element downstream of the B‐cell receptor and Fc‐receptors. Tolebrutinib (PRN2246, SAR442168) is a potent BTK inhibitor that covalently binds the kinase, resulti...

Full description

Bibliographic Details
Main Authors: Timothy D. Owens, Patrick F. Smith, Andrew Redfern, Yan Xing, Jin Shu, Dane E. Karr, Sonja Hartmann, Michelle R. Francesco, Claire L. Langrish, Philip A. Nunn, Steven G. Gourlay
Format: Article
Language:English
Published: Wiley 2022-02-01
Series:Clinical and Translational Science
Online Access:https://doi.org/10.1111/cts.13162

Internet

https://doi.org/10.1111/cts.13162

Similar Items